Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Toray and ASKA Terminate Business Collaboration Agreement for Adhesion Barrier Agent TRM-270

TOKYO, September 30, 2025 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), and Toray Industries, Inc. (Head Office: Chuo-ku, Tokyo; President: Mitsuo Ohya, hereinafter “Toray”) announced today that they have decided to terminate the business collaboration agreement for development and commercialization of an adhesion barrier agent (development code: TRM-270, hereinafter “Product”).

Toray and ASKA signed the business collaboration agreement in September 2021 to develop the Product, with the aim of obtaining manufacturing and marketing approval in Japan. However, as announced in the Company’s press release dated April 2025, titled “ASKA Announces Phase III Clinical Trial Result of TRM-270,” the phase III clinical trial of the Product failed to achieve the primary endpoint. Following this outcome, Toray and ASKA conducted a detailed analysis of the trial results and held extensive discussions regarding the development direction. As a result, they decided to terminate the agreement.

This matter will have no impact on the Company’s consolidated financial results for the current fiscal year.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp